Carsten-O Sahlmann1, Kia Homayounfar2, Martin Niessner2, Jerzy Dyczkowski3, Lena-Christin Conradi2, Friederike Braulke4, Birgit Meller1, Tim Beißbarth3, B Michael Ghadimi2, Johannes Meller1, David M Goldenberg5,6, Torsten Liersch2. 1. Department of Nuclear Medicine, University Medical Center Goettingen, Goettingen, Germany. 2. Department of General, Visceral, and Pediatric Surgery, University Medical Center Goettingen, Goettingen, Germany. 3. Department of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany. 4. Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany. 5. Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, New Jersey. 6. Immunomedics, Inc, Morris Plains, New Jersey.
Abstract
BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) 131 I-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m2 per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were "truly adjuvant." Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as "possibly nonadjuvant," but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N = 5) or relapse (N = 14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The "truly adjuvant" patients (N = 39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P < .001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P = .014), and CSS (not reached vs 41.4 months; hazard ratio,0.42; P = .014) compared with "possibly nonadjuvant" patients (N = 24). CONCLUSIONS: Repeated RIT with 131 I-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for "truly adjuvant" patients. However, the maximum safe dose of 131 I-labetuzumab is a single administration of 50 millicuries/m2 . Cancer 2017;123:638-649.
BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) 131 I-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m2 per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were "truly adjuvant." Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as "possibly nonadjuvant," but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N = 5) or relapse (N = 14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The "truly adjuvant" patients (N = 39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P < .001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P = .014), and CSS (not reached vs 41.4 months; hazard ratio,0.42; P = .014) compared with "possibly nonadjuvant" patients (N = 24). CONCLUSIONS: Repeated RIT with 131 I-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for "truly adjuvant" patients. However, the maximum safe dose of 131 I-labetuzumab is a single administration of 50 millicuries/m2 . Cancer 2017;123:638-649.
Authors: Benjamin Cahan; Lucille Leong; Lawrence Wagman; David Yamauchi; Stephen Shibata; Sharon Wilzcynski; Lawrence E Williams; Paul Yazaki; David Colcher; Paul Frankel; Anna Wu; Andrew Raubitschek; John Shively; Jeffrey Y C Wong Journal: Cancer Biother Radiopharm Date: 2017-09 Impact factor: 3.099
Authors: L S F Boogerd; F A Vuijk; C E S Hoogstins; H J M Handgraaf; M J M van der Valk; P J K Kuppen; C F M Sier; C J H van de Velde; J Burggraaf; A Fariña-Sarasqueta; Alexander L Vahrmeijer Journal: Biomark Cancer Date: 2017-05-17
Authors: Charlotte E S Hoogstins; Leonora S F Boogerd; Babs G Sibinga Mulder; J Sven D Mieog; Rutger Jan Swijnenburg; Cornelis J H van de Velde; Arantza Farina Sarasqueta; Bert A Bonsing; Berenice Framery; André Pèlegrin; Marian Gutowski; Françoise Cailler; Jacobus Burggraaf; Alexander L Vahrmeijer Journal: Ann Surg Oncol Date: 2018-07-26 Impact factor: 5.344
Authors: Leonora Sf Boogerd; Maxime Jm van der Valk; Martin C Boonstra; Hendrica Ajm Prevoo; Denise E Hilling; Cornelis Jh van de Velde; Cornelis Fm Sier; Arantza Fariña Sarasqueta; Alexander L Vahrmeijer Journal: Onco Targets Ther Date: 2018-03-23 Impact factor: 4.147